SCHEMBL6085891

SCHEMBL6085891

CC(C)(C)CC(=O)Nc1cccc(-c2n[nH]cc2-c2nc3cc(C(C)(C)C)ccc3o2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.47
KDM4E B2RXH2 3/20 0.47
MAPT P10636 3/20 0.47
TP53 P04637 1/20 0.47
P2RY14 Q15391 8/20 0.47
USP2 O75604 3/20 0.45
ALDH1A1 P00352 3/20 0.45
TSHR P16473 2/20 0.45
MAPK1 P28482 2/20 0.45
POLB P06746 2/20 0.45
NPC1 O15118 2/20 0.45
GAA P10253 2/20 0.45
HPGD P15428 2/20 0.45
RAB9A P51151 2/20 0.45
THRB P10828 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085604 0.90 P2RY14 (0.55) HSD17B10KDM4EMAPTTP53P2RY14
SCHEMBL6083799 0.89 HSD17B10 (0.48) HSD17B10KDM4EMAPTTP53P2RY14
SCHEMBL6222058 0.89 HSD17B10 (0.47) HSD17B10KDM4EMAPTTP53P2RY14
SCHEMBL6086468 0.88 HSD17B10 (0.47) HSD17B10KDM4EMAPTTP53P2RY14
SCHEMBL6085196 0.88 P2RY14 (0.63) MAPTTP53P2RY14RXFP1
SCHEMBL6085660 0.86 P2RY14 (0.49) KDM4ETP53P2RY14KMT2A
SCHEMBL6085535 0.85 NPC1 (0.59) HSD17B10KDM4EMAPTTP53P2RY14
SCHEMBL6084520 0.85 MAPT (0.46) HSD17B10KDM4EMAPTTP53ALDH1A1
SCHEMBL6085471 0.84 MAPT (0.44) KDM4EMAPTTP53P2RY14USP2
SCHEMBL6086190 0.83 MAPT (0.49) HSD17B10MAPTTP53USP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 HSD17B10 3948/4885KDM4E 1175/4885MAPT 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.